Haifa company granted US patent for skeletal muscle regeneration

The patent was granted for the use of mesenchymal stem cells in skeletal muscle regeneration either directly after, or shortly after post-surgical muscle injury.

November 26, 2017 01:53
1 minute read.

PLURISTEM CHAIRMAN AND CO-CEO Zami Aberman holds a vial of specialized stem cells the company calls ‘the next generation of biological therapeutic products.’. (photo credit: COURTESY PLURISTEM)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Stem cells will soon be used to regenerate injured muscles now that the US Patent and Trademark Office on Thursday issued a patent to Haifa-based Pluristem Therapeutics Inc.

The patent – which has already been granted in Europe, Hong Kong and Israel – was granted for the use of mesenchymal stem cells in skeletal muscle regeneration either directly after, or shortly after, post-surgical muscle injury.

“This very important patent comes at the right time, just ahead of our planned Phase III study in muscle regeneration following hip fracture,” said Pluristem chairman and co-CEO Zami Aberman. “The patent substantially strengthens our intellectual property around muscle regeneration, particularly as it pertains to repair and regeneration following surgery. In an industry that demands constant technological and scientific advances, a robust patent portfolio covering our core innovations strengthens Pluristem’s competitive edge.”

Pluristem received approval from the US Food and Drug Administration and the European Medicine Agency to test its treatment of muscle recovery following arthroplasty for hip fractures. This planned study was recently awarded $8.7 million by the Horizon 2020 program, the European Union’s largest research and innovation program.

Previous clinical studies using PLX-PAD, or placental- derived adherent stromal, cells demonstrated significant muscle regeneration following an arthroplasty orthopedic surgical procedure.

Those studies showed a 300% improvement in muscle volume and a 500% boost in muscle force six months after surgery compared to the control group.

If the new study is successful, Pluristem plans to use the results to obtain marketing approval in the US and Europe.

Pluristem is a leading developer of placenta-based cell therapy products, and one of the first to use the products, which have begun to be used more frequently in recent years. Today, the Human Placenta Project, a collaborative research effort launched by the National Institute of Child Health and Human Development, is helping the medical community understand the role of the placenta in human health. When Pluristem started, the technology was largely untapped.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

Wildfires in Mevo Modi'm, May 23, 2019
May 26, 2019
Jewish Agency to provide aid to victims of Israeli wildfires